Send to

Choose Destination
Oncol Rep. 2018 Apr;39(4):2006-2014. doi: 10.3892/or.2018.6243. Epub 2018 Feb 1.

β3GnT8 regulates oxaliplatin resistance by altering integrin β1 glycosylation in colon cancer cells.

Author information

Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Department of Biochemistry, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
2014 Biological Sciences, School of Biomedical Engineering, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.


Correlations between drug resistance and glycosylation changes have been analyzed intensively in the field of tumor biology. The present study was aimed to investigate the glycan and glycogene alterations involved in oxaliplatin resistance in human colon cancer cells. Using the lectin microarray for glycan composition and FITC-lectin binding for glycan profiling, we found that polylactosamine-type N-glycans were significantly increased in oxaliplatin-resistant SW620R cells. Using real-time PCR for quantification of glycogenes, we targeted β-1,3-N-acetylglucosaminyltransferase 8 (β3GnT8), which was overexpressed in SW620R cells. Using an RNA interference strategy, we revealed that the silencing of β3GnT8 in SW620R cells resulted in increased chemosensitivity to oxaliplatin. Conversely, the engineered overexpression of β3GnT8 in SW620 cells enhanced resistance to oxaliplatin. Further data revealed that manipulation of β3GnT8 was able to modify polylactosamine chains on integrin β1 and to regulate the integrin β1 downstream signaling pathway. These results revealed that β3GnT8 may play a key role in the development of oxaliplatin resistance in colon cancer cells possibly through the alteration of the glycosylation of integrin β1. These findings may be valuable for overcoming drug resistance in colon cancer.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Spandidos Publications
Loading ...
Support Center